SCHEMBL6032141

SCHEMBL6032141

Clc1ccc(N2CCN(Cc3ccccc3Cl)CC2)cc1Cl

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.73
KDM4E B2RXH2 5/20 0.73
MAPT P10636 3/20 0.73
GAA P10253 1/20 0.73
HTT P42858 1/20 0.72
PLA2G1B P04054 1/20 0.65
RAB9A P51151 1/20 0.65
ATG4B Q9Y4P1 1/20 0.65
DRD2 P14416 5/20 0.60
DRD4 P21917 5/20 0.60
DRD3 P35462 3/20 0.60
DRD1 P21728 1/20 0.60
DRD5 P21918 1/20 0.60
SIGMAR1 Q99720 1/20 0.59
SMN1; SMN2 Q16637 3/20 0.58
TDP1 Q9NUW8 1/20 0.58
HTR1A P08908 1/20 0.55
ADRA1D P25100 1/20 0.55
ADRA1A P35348 1/20 0.55
ADRA1B P35368 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6806255 0.84 ALDH1A1 (0.68) ALDH1A1KDM4EMAPTGAAHTT
Bromide SCHEMBL6030909 0.82 ALDH1A1 (0.73) ALDH1A1KDM4EMAPTGAAHTT
SCHEMBL5541685 0.82 KDM4E (0.78) ALDH1A1KDM4EMAPTGAAHTT
SCHEMBL5541696 0.82 KDM4E (0.78) ALDH1A1KDM4EMAPTGAAHTT
SCHEMBL6031004 0.82 ALDH1A1 (0.78) ALDH1A1KDM4EMAPTGAAHTT
SCHEMBL11360607 0.82 SIGMAR1 (0.85) ALDH1A1KDM4EMAPTGAAHTT
SCHEMBL6031039 0.81 ALDH1A1 (0.71) ALDH1A1KDM4EMAPTGAAHTT
SCHEMBL7521522 0.81 ALDH1A1 (0.63) ALDH1A1KDM4EMAPTGAAHTT
SCHEMBL6411597 0.79 ALDH1A1 (1.00) ALDH1A1KDM4EMAPTGAAHTT
SCHEMBL6031654 0.78 MAPT (0.65) ALDH1A1KDM4EMAPTGAADRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7101887-B2 1-phenyl-4-benzylpiperazines dopamine receptor subtype specific ligands NEUROGEN CORPORATION (US) 2006-09-05 US disclosed
US-20050239799-A1 1-phenyl-4-benzylpiperazines dopamine receptor subtype NEUROGEN CORPORATION (US) 2005-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050239799-A1 1-phenyl-4-benzylpiperazines dopamine receptor subtype DRD2, DRD4, HTR2C ALDH1A1 567/4885KDM4E 3595/4885MAPT 1859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.